We are developing novel cancer therapeutics designed to spare healthy cells while targeting tumor adaptive responses and cancer evasion pathways. Our primary therapeutic focus is the GAS6-AXL pathway, where we can interrupt oncogenic signals and use our high-affinity decoy receptors to outcompete cancer’s ability to grow, spread, and acquire therapeutic resistance.
Aravive’s products in development are based on technology originated at Stanford University. The company is based in Houston, Texas and funded in part by a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT).
04 June 2018 | Versartis Aravive Proposed Merger Presentation